GRPR and neoplasm: Nonetheless, GRPR antagonists have demonstrated superior pharmacokinetic properties and high tumor accumulation in several in vivo models, emerging as a valuable alternative in the development of GRPR-targeting radiopharmaceuticals [9,10,11,12,13].